- Home
- CERT vs TRVI Comparison
CERT vs TRVI Comparison
Compare CERT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CERT | TRVI |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CERT | TRVI |
|---|---|---|
| Price | $7.29 | $11.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $12.78 | ★ $20.38 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 02-26-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $415,551,000.00 | N/A |
| Revenue This Year | $10.75 | N/A |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $109.10 | ★ N/A |
| Revenue Growth | ★ 11.47 | N/A |
| 52 Week Low | $7.30 | $3.77 |
| 52 Week High | $15.69 | $14.39 |
Technical Indicators
Market Signals| Indicator | CERT | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 24.85 | 52.65 |
| Support Level | $7.49 | $10.72 |
| Resistance Level | $10.21 | $11.93 |
| Average True Range (ATR) | 0.44 | 0.72 |
| MACD | -0.27 | 0.14 |
| Stochastic Oscillator | 2.38 | 76.63 |
Price Performance
Historical ComparisonAbout CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.